🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Emily Y. Jen

United States Food and Drug Administration

ORCID: 0000-0003-1962-5708
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy”.

FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4525
N/A
0DataRank · unranked
25 citations

Xin Wang, Meng Li, Hongshan Li, Shwu‐Luan Lee, Nina Ni +9 more

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3579
N/A
0DataRank · unranked
11 citations

Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru +7 more

Considerations for Drug Development in Myelodysplastic Syndromes

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3348
N/A
0DataRank · unranked
12 citations

Nina Kim, Amy E. DeZern, Kelly J. Norsworthy, Jacqueline S. Garcia, R. Angelo de Claro +6 more

Advancing drug development in myelodysplastic syndromes

Blood Advances(2024)10.1182/bloodadvances.2024014865
N/A
0DataRank · unranked
12 citations

Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo +17 more